2024年中国肺移植基础研究年度盘点OA北大核心
Annual review of basic research on lung transplantation of China in 2024
肺移植是终末期肺病的最佳治疗方式,可显著改善患者预后.但感染、排斥反应、缺血-再灌注损伤等术后并发症,以及其他挑战(如供肺短缺),限制了肺移植在临床中的实际应用.我国科研团队持续努力,通过融合新兴技术与多学科交叉领域的前沿成果,在肺移植基础研究方面取得突破性进展,有力推动了该领域的发展.本文将全面梳理我国研究团队在 2024年于肺移植领域所取得的学术进展,重点关注中国团队在肺移植基础研究领域取得的进展,为肺移植基础领域的关键问题提供创新思路与策略,助力我国肺移植事业迈向更高水平.
Lung transplantation is the optimal treatment for end-stage lung diseases and can significantly improve prognosis of the patients.However,postoperative complications such as infection,rejection,ischemia-reperfusion injury,and other challenges(like shortage of donor lungs),limit the practical application of lung transplantation in clinical practice.Chinese research teams have been making continuous efforts and have achieved breakthroughs in basic research on lung transplantation by integrating emerging technologies and cutting-edge achievements from interdisciplinary fields,which has strongly propelled the development of this field.This article will comprehensively review the academic progress made by Chinese research teams in the field of lung transplantation in 2024,with a focus on the achievements of Chinese teams in basic research on lung transplantation.It aims to provide innovative ideas and strategies for key issues in the basic field of lung transplantation and to help China's lung transplantation cause reach a higher level.
马吉尔;田东;朱峻民;张镧;靳小汉;郑翔匀;侯森林;喻赠玮;刘亚灵;严浩吉
610041 成都,四川大学华西临床医学院四川大学华西医院胸外科||四川大学华西医院胸部肿瘤研究所肺移植研究室610041 成都,四川大学华西临床医学院610041 成都,四川大学华西临床医学院610041 成都,四川大学华西临床医学院四川大学华西医院胸外科四川大学华西医院胸部肿瘤研究所肺移植研究室四川大学华西医院胸部肿瘤研究所肺移植研究室四川大学华西医院胸部肿瘤研究所肺移植研究室四川大学华西医院胸部肿瘤研究所肺移植研究室
临床医学
肺移植感染排斥反应免疫耐受缺血-再灌注损伤慢性移植肺功能障碍宏基因组二代测序原发性移植物功能障碍
Lung transplantationInfectionRejectionImmune toleranceIschemia-reperfusion injuryChronic lung allograft dysfunctionMetagenomic next-generation sequencingPrimary graft dysfunction
《器官移植》 2025 (3)
386-393,8
国家自然科学基金(82470104)
评论